首页> 美国卫生研究院文献>PLoS Neglected Tropical Diseases >Characterization of Rift Valley Fever Virus MP-12 Strain Encoding NSs of Punta Toro Virus or Sandfly Fever Sicilian Virus
【2h】

Characterization of Rift Valley Fever Virus MP-12 Strain Encoding NSs of Punta Toro Virus or Sandfly Fever Sicilian Virus

机译:裂谷热病毒MP-12株编码蓬塔托罗病毒或沙蝇热西西里病毒的NSs的表征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Rift Valley fever virus (RVFV; genus Phlebovirus, family Bunyaviridae) is a mosquito-borne zoonotic pathogen which can cause hemorrhagic fever, neurological disorders or blindness in humans, and a high rate of abortion in ruminants. MP-12 strain, a live-attenuated candidate vaccine, is attenuated in the M- and L-segments, but the S-segment retains the virulent phenotype. MP-12 was manufactured as an Investigational New Drug vaccine by using MRC-5 cells and encodes a functional NSs gene, the major virulence factor of RVFV which 1) induces a shutoff of the host transcription, 2) inhibits interferon (IFN)-β promoter activation, and 3) promotes the degradation of dsRNA-dependent protein kinase (PKR). MP-12 lacks a marker for differentiation of infected from vaccinated animals (DIVA). Although MP-12 lacking NSs works for DIVA, it does not replicate efficiently in type-I IFN-competent MRC-5 cells, while the use of type-I IFN-incompetent cells may negatively affect its genetic stability. To generate modified MP-12 vaccine candidates encoding a DIVA marker, while still replicating efficiently in MRC-5 cells, we generated recombinant MP-12 encoding Punta Toro virus Adames strain NSs (rMP12-PTNSs) or Sandfly fever Sicilian virus NSs (rMP12-SFSNSs) in place of MP-12 NSs. We have demonstrated that those recombinant MP-12 viruses inhibit IFN-β mRNA synthesis, yet do not promote the degradation of PKR. The rMP12-PTNSs, but not rMP12-SFSNSs, replicated more efficiently than recombinant MP-12 lacking NSs in MRC-5 cells. Mice vaccinated with rMP12-PTNSs or rMP12-SFSNSs induced neutralizing antibodies at a level equivalent to those vaccinated with MP-12, and were efficiently protected from wild-type RVFV challenge. The rMP12-PTNSs and rMP12-SFSNSs did not induce antibodies cross-reactive to anti-RVFV NSs antibody and are therefore applicable to DIVA. Thus, rMP12-PTNSs is highly efficacious, replicates efficiently in MRC-5 cells, and encodes a DIVA marker, all of which are important for vaccine development for Rift Valley fever.
机译:裂谷热病毒(RVFV;静脉病毒属,布尼亚病毒科)是一种由蚊子传播的人畜共患病原体,可引起人类出血热,神经系统疾病或失明,反刍动物的流产率很高。 MP-12菌株是一种减毒活疫苗,在M和L片段中减毒,但S片段保留有毒的表型。 MP-12是使用MRC-5细胞制成的试验性新疫苗疫苗,编码功能性NSs基因,即RVFV的主要毒力因子,其1)诱导宿主转录的关闭,2)抑制干扰素(IFN)-β启动子激活; 3)促进dsRNA依赖性蛋白激酶(PKR)的降解。 MP-12缺乏区分感染动物和疫苗接种动物(DIVA)的标记。尽管缺少NS的MP-12可用于DIVA,但它无法在具有I型IFN能力的MRC-5细胞中有效复制,而具有I型IFN能力的细胞的使用可能会对其遗传稳定性产生负面影响。为了生成编码DIVA标记的修饰MP-12候选疫苗,同时仍能在MRC-5细胞中有效复制,我们生成了编码MP-12的重组MP-12,编码蓬塔托罗病毒Adames株NSs(rMP12-PTNSs)或桑蝇西西里病毒NSs(rMP12- SFSNS)代替MP-12 NS。我们已经证明那些重组MP-12病毒抑制IFN-βmRNA的合成,但不促进PKR的降解。在MRC-5细胞中,rMP12-PTNSs(而非rMP12-SFSNSs)比缺少NSs的重组MP-12更有效地复制。接种了rMP12-PTNSs或rMP12-SFSNSs的小鼠诱导中和抗体的水平与接种MP-12的小鼠相同,并且可以有效地保护其免受野生型RVFV攻击。 rMP12-PTNS和rMP12-SFSNS不诱导与抗RVFV NSs抗体发生交叉反应的抗体,因此适用于DIVA。因此,rMP12-PTNSs高效,可在MRC-5细胞中高效复制并编码DIVA标记,所有这些对于裂谷热疫苗的开发都很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号